Drug Profile
Fianlimab - Regeneron Pharmaceuticals
Alternative Names: Anti-LAG-3 antibody; REGN-3767Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Malignant melanoma
- Phase II/III Non-small cell lung cancer
- Phase II Solid tumours
- Phase I Haematological malignancies
Most Recent Events
- 07 Feb 2024 Regeneron Pharmaceuticals plans phase-III trial for Malignant melanoma (Unresectable/Inoperable, Metastatic disease, Combination therapy, Late-stage disease) in June 2024 (IV) (NCT06246916)
- 25 Jan 2024 Updated efficacy and adverse events data from a phase I trial in haematological malignancies presented at the 2024 Genitourinary Cancers Symposium (ASCO-GCS-2024)
- 16 Jan 2024 Regeneron Pharmaceuticals in collaboration with Sidney Kimmel Comprehensive Cancer Center plans a phase II trial for Colorectal cancer (Combination therapy, Late-stage disease, In the elderly, First-line therapy) in USA (IV) in May 2024 (NCT06205836)